Insights Into Breast Cancer 2025
Perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative breast cancer (TNBC), and attitudes toward recently introduced and upcoming agents in relapsed/refractory disease
Faculty Chair
Neil Lyengar, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Faculty Chair
Reshma Mahtani, MD
Baptist Health South Florida, Plantation, FL, USA
Faculty Chair
Jason Mouabbi, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Chair
Jason Mouabbi, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Chair
Kit Lu, MD
University of Pittsburgh Medical Center, Colonial Park, PA, USA
More Information
- Virtual series
- New England
More Information
- Atlanta, GA
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Dallas, TX
- Arkansas, Kansas, Louisiana, Missouri, Oklahoma, Texas
More Information
- Phoenix, AZ
- Arizona, Colorado, Nevada, New Mexico, Southern California, Utah
More Information
- VA
- DC (Virginia side)
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of breast cancer
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained
- HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, and chemotherapies
- HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, trastuzumab deruxtecan, tucatinib, neratinib, AIs, and chemotherapies
- TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan), immunotherapy, and chemotherapies
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
